Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.
2.

Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen.

Chang SS, Reuter VE, Heston WD, Gaudin PB.

Urology. 2001 Apr;57(4):801-5.

PMID:
11306418
3.

Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.

Genega EM, Hutchinson B, Reuter VE, Gaudin PB.

Mod Pathol. 2000 Nov;13(11):1186-91.

4.

Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy.

Gong MC, Chang SS, Watt F, O'Keefe DS, Bacich DJ, Uchida A, Bander NH, Reuter VE, Gaudin PB, Molloy PL, Sadelian M, Heston WD.

Mol Urol. 2000 Fall;4(3):217-22;discussion 223. Review.

PMID:
11062377
5.

Prostate-Specific Membrane Antigen: Much More Than a Prostate Cancer Marker.

Chang SS, Gaudin PB, Reuter VE, O'Keefe DS, Bacich DJ, Heston WD.

Mol Urol. 1999;3(3):313-320.

PMID:
10851338
6.

Prostate-specific membrane antigen: present and future applications.

Chang SS, Gaudin PB, Reuter VE, Heston WD.

Urology. 2000 May;55(5):622-9. Review. No abstract available.

PMID:
10792065
7.

Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.

Chang SS, Reuter VE, Heston WD, Hutchinson B, Grauer LS, Gaudin PB.

Cancer. 2000 Jan 15;88(2):407-15.

PMID:
10640975
8.

Prostate-specific membrane antigen is produced in tumor-associated neovasculature.

Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB.

Clin Cancer Res. 1999 Oct;5(10):2674-81.

9.

Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues.

Gaudin PB, Zelefsky MJ, Leibel SA, Fuks Z, Reuter VE.

Am J Surg Pathol. 1999 Sep;23(9):1021-31.

PMID:
10478661
10.

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB.

Cancer Res. 1999 Jul 1;59(13):3192-8.

11.

Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection.

Harrison LE, Gaudin PB, Brennan MF.

Arch Surg. 1999 Feb;134(2):181-5.

PMID:
10025460
12.

Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma.

Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI.

J Natl Cancer Inst. 1998 Sep 2;90(17):1284-91.

PMID:
9731735
13.

Pathologic features from prostate needle biopsy and prognosis after I-125 brachytherapy.

Grann A, Gaudin PB, Raben A, Wallner K.

Radiat Oncol Investig. 1998;6(4):170-4.

PMID:
9727876
14.

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z.

Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):491-500.

PMID:
9635694
15.

Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases.

Gaudin PB, Rosai J, Epstein JI.

Am J Surg Pathol. 1998 Feb;22(2):148-62. Review.

PMID:
9500215
16.

Accuracy of grading gliomas on CT-guided stereotactic biopsies: a survival analysis.

Gaudin PB, Sherman ME, Brat DJ, Zahurak M, Erozan YS.

Diagn Cytopathol. 1997 Dec;17(6):461-6.

PMID:
9407209
17.

Renal oncocytoma: a clinicopathologic study of 70 cases.

Perez-Ordonez B, Hamed G, Campbell S, Erlandson RA, Russo P, Gaudin PB, Reuter VE.

Am J Surg Pathol. 1997 Aug;21(8):871-83.

PMID:
9255250
18.

Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens.

Gaudin PB, Sesterhenn IA, Wojno KJ, Mostofi FK, Epstein JI.

Urology. 1997 Apr;49(4):558-63.

PMID:
9111625
19.

Benign mimics of prostatic adenocarcinoma on needle biopsy.

Gaudin PB, Reuter VE.

Anat Pathol. 1997;2:111-34. Review.

PMID:
9575372
20.

Microsatellite instability is uncommon in uterine serous carcinoma.

Tashiro H, Lax SF, Gaudin PB, Isacson C, Cho KR, Hedrick L.

Am J Pathol. 1997 Jan;150(1):75-9.

Supplemental Content

Loading ...
Support Center